Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten

W. Schneider

doi:10.1055/s-0038-1659946

Hämostaseologie, Table of Contents

Hamostaseologie 1988; 08(01): 34-46
DOI: 10.1055/s-0038-1659946

Originalarbeiten

Schattauer GmbH

Bedeutung von Hämostasestörungen für Diagnostik und Therapie von Tumorkrankheiten

W. Schneider

¹Medizinische Klinik und Poliklinik, Universität Düsseldorf

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Ambrus J.L, Ambrus C.M. Blood coagulation in neoplastic disease. In: Onkohämo-staseologie. Gastpar H. (ed) Stuttgart: Schattauer; 1976: 167-173.
2 Barrett O.J. The peripheral blood in malignancy. General Practice 1970; 2: 95-100.
3 Berger H, Freudenberg N. Todesursachen bei Malignompatienten. Med Welt 1983; 34: 112-118.
4 Bessler H, Notti I, Djaldetti M. The effect of partial splenectomy on platelet production in mice. Thromb Haemostas (Stuttgart) 1981; 46: 602-603.
5 Bick R.L. Alterations of hemostasis in malignancy. In: Disorders of Hemostasis and Thrombosis. Bick R.L. (ed) Principles of Clinical Practice. New York: Thieme Ine; 1985: 262-287.
6 Billroth S. Lectures on surgical pathology and therapeutics. Translated from the 8th ed. London: New Sydenham Society; 1878
7 Bizzozero J. Über einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Vir-chows Arch path Anat Physiol klin Med 1982; 90: 261-332.
8 Boxer M.A, Braun J, Ellman L. Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg 1978; 113: 808-9.
9 Burstein S.A, Erb S.K, Adamson J.W, Harker L.A. Immunologie stimulation of early murine hematopoiesis and its abrogation by cyclosporin A. Blood 1982; 59: 851-856.
10 Burstein S.A. Interleukin 3 promotes maturation of murine megakaryocytes in vitro. Blood Cells 1986; 11: 469-479.
11 Cavender D.E, Haskard D.O, Joseph B, Ziff M. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J Immunol 1986; 136: 203-207.
12 Cheng K, Kummer H. Thrombozytose bei Bronchuskarzinom. Schweiz Med Wo-chenschr 1970; 100: 2003.
13 Cline M.J. Monocytes and macrophages: functions and diseases. Ann Intern Med 1978; 88: 78-88.
14 Cooper E.H, Stone J. Acute phase reactant proteins in cancer. Adv Cane Res 1979; 30: 1-44.
15 Crabtree G.R. The molecular biology of fibrinogen. In: The Molecular Basis of Blood Diseases. Stamatoyannopoulos G, Nienhuis A.W, Leder Ph, Majerus P.h.W. (eds) Philadelphia: Saunders Comp; 1987: 631-61.
16 Crowther D, Bateman C.J.T. Malignant disease. Clin Haematol 1972; 1: 447-473.
17 Davis W.M, Mendez Ross A.O. Thrombocytosis and thrombocythemia: The laboratory and clinical significance of an elevated platelet count. Am J Clin Path 1973; 59: 243-247.
18 Diehl W.L, Mandelbaum I. The significance of thrombocytosis in patients with carcinoma of the lung. Surg Gynec Obstet 1983; 156: 187-188.
19 Dinarello C.A. Interleukin-1 and the pathogenesis of the acute phase response. New Engl J Med 1984; 311: 1413-1418.
20 Donati M.B, Poggi A, Semeraro N. Coagulation and malignancy. In: Recent Advances in Blood Coagulation 3. Poller L. (ed) Edinburgh, London, Melbourne, New York: Churchill Livingstone; 1981: 227-259.
21 Ernst E. Leukozytenzahl - ein Risikoindikator kardiovaskulärer Erkrankungen?. Herz/Kreisl 1987; 19: 108-112.
22 Geissler D, Konwalinka G, Peschel C, Grünewald K, Odavic R, Braunsteiner H. A regulatory role of activated T-lymphocytes on human megakaryocytopoiesis in vitro. Brit J Haematol 1985; 60: 233-238.
23 Geissler K, Korninger C, Niessner H, Lechner K. Verbrauchskoagulopathie bei malignen Tumoren. Blut 1983; 47: 179 (Abstract)
24 Gunzenbach R, Grimm J, Trachsler M, Rhyner K. Häufigkeit und klinische Relevanz von Thrombozytosen. Schweiz Med Wochenschr 1982; 112: 38-41.
25 Gordon S.G. Tumorprokoagulans, Gerinnung und Fibrinolyse bei malignen Erkrankungen. Hämostaseologie 1985; 5: 160-165.
26 Gordon D.H, Schaffner D, Bennett J.M, Schwartz S.I. Postsplenectomy thrombocytosis. Its association with mesenteric, portal, and/or renal vein thrombosis in patients with myeloproliferative disorders. Arch Surg 1978; 113: 713-715.
27 Greenberger J.S, Krensky A.M, Messner H, Burakoff S.J, Wandl U, Sakakeeny M.A. Production of colony-stimulating factor(s) for granulocyte macrophage and multipo-tential (granulocyte/erythroid/megakaryo-cyte/macrophage) hematopoietic progenitor cells (CFU-GEMM) by clonal lines of human IL-2-dependent T-lymphocytes. Exp Hematol 1984; 12: 720-722.
28 Grimm R.H, Neaton J.D, Ludwig W. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985; 254: 1932-1937.
29 Hagedorn A.B, Bowie E.J.W, Elveback L.R, Owen C.A. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1974; 49: 649-653.
30 Harker L.A, Finch C.A. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974.
31 Helbig W. Zur Wertigkeit paraneoplastischer Knochenmark- und Blutbildbefunde. Verh Dtsch Ges Inn Med 1980; 86: 428-432.
32 Hirsh J. Hypercoagulability. Sem Hematol 1977; 14: 409-425.
33 Ho W.G, Winston D.J. Transfusions and supportive care. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 239-247.
34 Kanz L, Lohr G.W, Fauser A.A. Human megakaryocytic progenitor cells. Klin Wochenschr 1987; 65: 297-307.
35 Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636-641.
36 Kessler C.M, Klein H.G, Havlik R.J. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Brit J Haematol 1982; 50: 157-167.
37 Koeffler H Ph, Amatruda Th T. Preleukemia. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 197-212.
38 Korninger C, Deutsch E. The role of hae-mostasis in malignancy. In: The Cancer Patient. Cancer Campaign, vol 9. Beck L, Grundmann E, Schneider W. (eds) Stuttgart, New York: Fischer; 1985: 79-84.
39 Kostis J.B, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography. Am J Cardiol 1984; 53: 997-999.
40 Levin J, Conley C.D. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114: 497-500.
41 Lovett D, Kozan B, Hadam M, Resch K, Gemsa D. Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol 1986; 136: 340-347.
42 Marx R. Wichtige klinisch-hämostaseologi-sche Phänomene bei Malignomen. In: On-kohämostaseologie. Gastpar H. (ed) Stuttgart, New York: Schattauer; 1976: 3-20.
43 Mason J.E, De Vita V.T, Canellos G.P. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974; 44: 483-487.
44 Mayr A.C, Dick H.J, Nagel G.A, Senn H.J. Thrombozytose bei malignen Tumoren. Schweiz Med Wochenschr 1973; 103: 1626-1629.
45 Minar E, Ehringer H, Marosi L, Hiischi M, Konecny U, Pollak Ch, Czembirek H, Sommer G. Akute Venenthrombose. Lokalisation, Ausdehnung und Ätiologie mit besonderer Berücksichtigung der Paraneoplasie. Dtsch Med Wochenschr 1982; 107: 1303-1309.
46 Monick M, Glazier J, Hunninghake G.W. Human alveolar macrophages suppress in-terleukin-1 (IL-1) activity via the secretion of prostaglandin E₂ . Am Rev Respir Dis 1987; 135: 72-77.
47 Morley A.A, Baikie A.G, Galton D.A.G. Cyclic leucocytosis as evidence for retention of normal homoeostatic control in chronic granulocytic leukaemia. Lancet 1967; II: 1320-1323.
48 Morowitz D.A, Allen L.W, Kirsner J.B. Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968; 68: 1013-1021.
49 Mosher D.F. Fibronectin. Progr Hemost Thrombos 1980; 5: 111-151.
50 Munzarova M, Kovarik J. Ist Krebs eine makrophagenvermittelte Autoimmunerkrankung?. The Lancet (deutsche Ausgabe) 1987; 1: 571-574.
51 Murphy S. Thrombocytosis and thrombo-cythaemia. Clin Haematol 1983; 12: 89-106.
52 Nakano T, Fujii J, Tamura S, Hada T, Hagashino K. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer 1986; 58: 1699-1701.
53 O’Neill B. Monocytosis in malignant disease. Ann Intern Med 1970; 73: 991-992.
54 Odell W.D, Wolfsen A.R. Humoral syndromes associated with cancer. Ann Rev Med 1978; 29: 379-406.
55 Ouesenberry P.J, Ihle J.N, McGrath E. The effect of interleukin 3 and GM-CSA-2 on megakaryocyte and myeloid clonal colony formation. Blood 1985; 65: 214-217.
56 Rabellino E.M, Levene R.B, Nachman R.L, Leung L. Human megakaryocytes III. Characterization in myeloproliferative disorders. Blood 1984; 63: 615-622.
57 Rasche H. Hämostasedefekte durch Umsatzstörungen bei soliden Tumoren und malignen hämatologischen Systemerkrankungen. In: Handbuch der Inneren Medizin, Bd. 2, Teil 9:Blutgerinnung und hämorrhagische Diathesen II. Heene D.L. (Hrsg) Berlin, Heidelberg, New York: Springer.; 1985: 650-674.
58 Rickles F.R, Edwards R.L. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
59 Riess L. Zur pathologischen Anatomie des Blutes. Arch Anat Physiol Wissensch Med 1872; 237-249.
60 Robbins G, Barnard D.L. Thrombocytosis and Microthrombocytosis : A clinical evaluation of 372 cases. Acta Haematol 1983; 70: 175-182.
61 Ruff M.R, Pert C.B. Small cell carcinoma of the lung: macrophage-specific antigens suggest hemopoietic stem cell origin. Science 1984; 225: 1034-1036.
62 Sack G.H, Levin J, Bell W.R. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 1-37.
63 Schafer A.I. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12.
64 Scharf R.E, Theis O, Schneider W. Plättchensekretion und Thrombinaktivität bei Malignompatienten . Hämostaseologie 1985; 5: 166-169.
65 Schneider W. Unveröffentlichte Befunde.
66 Schneider W. Küche O. 2-h-Wert der Blutkörperchensenkung. Intern Praxis 1987; 27: 453-454.
67 Schneider W, Morgenstern E. Zellbiologische Grundlagen der Plättchenfunktion. In: Praktische Anwendung der Thrombozyten -funktionsdiagnostik. von Voss H, Göbel U. (Hrsg) Stuttgart: Thieme; 1980: 1-16.
68 Schneider W, Scharf R.E, Hagen-Aukamp Ch, Winkelmann M. Evolution der Hämostase : Megakaryozyten-Blutplättchen-Sy-stem. Arzneim-Forsch/Drug Res 1983; 33 (11) 1351-1354.
69 Schneider W, Winkelmann M. Hematological tumor signs. In: The Cancer Patient. Cancer Campaign, vol 9. Beck L, Grundmann E, Schneider W. (eds) Stuttgart, New York: Fischer; 1985: 71-77.
70 Schwartz C.J, Valente A.J, Sprague E.A, Kelly J.L, Suenram C.A, Graves D.T, Rozek M.M, Edwards E.H, Delgado R. Monocyte-makrophage participation in atherogenesis : inflammatory components of pathogenesis. Semin Thromb Hemostas 1986; 12: 79-86.
71 Selroos O. Thrombocytosis. Acta Med Scand 1973; 193: 431-436.
72 Silvis S.E, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA 1970; 211: 1852-1853.
73 Silvis S.E, Turkbas N, Swaim W.R, Doscherholmen A. Thrombocytosis. A clinical evaluation of 322 patients. Minn Med 1969; 52: 1603-1607.
74 Slichter S.J, Harker L.A. Hemostasis and malignancy. Ann NY Acad Sci 1974; 230: 252-261.
75 Snipper L.E. Clinical implications of tumor cell heterogeneity. New Engl J Med 1986; 314: 1423-1431.
76 Spigel S.C, Mooney L.R. Extreme thrombocytosis associated with malignancy. Cancer 1977; 39: 339-341.
77 Stossel Th P. The molecular biology of phagocytes and the molecular basis of nonneoplastic phagocyte disorders. In: The Molecular Basis of Blood Diseases. Stama-toyannopoulos G, Nienhuis A.W, Leder Ph, Majerus P.h.W. (eds) Philadelphia: Saunders Comp; 1987: 499-533.
78 Sun N.C, McAfee W.M, Hum G.J, Weiner J.M. Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979; 71: 10-16.
79 Thaler E, Niessner H, Lechner K. Chronische Verbrauchskoagulopathie bei Carcinom. In: Onkohämostaseologie. Gastpar H. (Hrsg) Stuttgart: Schattauer; 1976: 201-204.
80 Thompson R.B, Stainsby D. The clinical and haematoiogical features of chronic granulocytic leukaemia in the chronic phase. In: Chronic Granulocytic Leukaemia. Shaw M.T. (ed) Eastbourne, New York : Praeger Publishers; 1982: 137-167.
81 Tranum B.L, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974; 84: 615-619.
82 Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de L’Hotel-Dieu de Paris. Balliere 1865; 3: 654-656.
83 Wegmann D. Paraneoplastische Thrombose - eine mortalitätsstatistische Untersuchung. Vasa 1981; 10: 111-118.
84 Wehmeier A, Scharf R.E, Schneider W. Thrombose und Blutungsneigung bei myeloproliferativen Erkrankungen. Hämostaseologie 1985; 5: 185-192.
85 Wilmanns W, Possinger K. Paraneoplastische Syndrome - eine Hilfe bei der Früherkennung maligner Tumoren ?. Verh Dtsch Ges Inn Med 1986; 92: 66-76.
86 Winkelmann M. DNA-Gehalt und Reifegrad der Megakaryozyten bei Erkrankungen mit Hämostasestörungen. Habilitationsschrift, Düsseldorf 1987.
87 Winkelmann M, Pfitzer P, Schneider W. Polyploidy of cells and tissues in relation to the ploidy of megakaryocytes. Klin Wochenschr (im Druck).
88 Winkelmann M, Stöckler J, Grasmuck J, Pfitzer P, Schneider W. Ploidy pattern of megakaryocytes in patients with metastatic tumors with and without paraneoplastic thrombosis and in controls. Haemostasis 1984; 14: 501-507.
89 Winston D.J, Ho W.G, Gale R.P, Champlin R.E. Prevention and treatment of infection in leukemia patients. In: Leukemia Therapy. Gale R.P. (ed) Boston: Blackwell Scientific Publications; 1986: 213-238.
90 Zacharski L.R. Biologische Grundlagen einer Antikoagulantienbehandlung bei Tumorkrankheiten. Hämostaseologie 1985; 5: 178-184.
91 Zöllner N. Der leise Beginn chronischer Krankheiten - Beiträge zu ihrer Frühsymptomatologie und zur Nosologie der Frühstadien - Einführung. Verh Dtsch Ges Inn Med 1986; 92: 1-2.